ICAM1 and acute lymphoblastic leukemia: Inhibiting ICAM-1 and VCAM-1, which respectively bind the integrins LFA-1 and VLA-4 that are expressed by T-ALL cells, or inhibiting FAK/PYK2 signaling reduced leukemia burden across multiple organs, including the spleen and liver, and prolonged mouse survival43.